1. The dose-response relationship between the oral anticoagulant, warfarin, and its effect on the metabolism of phylloquinone (vitamin K,) has been examined in normal male volunteer subjects.
there was a progressive increase in the excre tion of at least three abnormal aglycones of phylloquinone.
5. The doses or plasma concentrations of warfarin were related to the increase in phylloquinone epoxide in the plasma and to the decrease in the proportion of normal aglycones of phylloquinone in urine by typical log dose-
Introduction
Over the last few years evidence has grown that the ability of coumarin and indanedione anticoagulants such as warfarin and phenindione to interfere with the synthesis of the vitamin K-dependent clotting factors is linked to the inhibition of a specific enzymic step in the metabolism of vitamin K itself. During the normal synthesis of factors I1 (prothrombin), VII, IX and X it has been postulated that vitamin K shuttles between its native biologically active form and an inactive 2gepoxide metabolite (Bell Uc . Since the work concerning this aspect of vitamin K metabolism has utilized phylloquinone (vitamin K1), the cyclic interconversion between the vitamin and its 2,3epoxide metabolite has been termed the vitamin K1-epoxide cycle.
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This cycle depends upon at least two enzymes, which have been partially characterized as phylloquinone epoxidase (Willingham & Matschiner, 1974) and phylloquinone epoxide reductase (Matschiner, Zimmerman & Bell, 1974; . Matschiner et al. (1974) have shown that warfarin inhibits phylloquinone epoxide reductase in uitro, thus explaining their earlier findings that in uiuo large amounts of phylloquinone 2,3-epoxide accumulated in the livers of warfarin-treated rats (Matschiner, Bell, Amelotti & Knauer, 1970) . They have further proposed that the vitamin K-dependent step in the synthesis of the clotting factors is linked to the epoxidation of the vitamin (Willingham & Matschiner, 1974) and that the role of the reductase is to regenerate vitamin K (Zimmerman .
In clinical practice, where oral anticoagulants are widely used for the prophylaxis and treatment of thromboembolic disease, all the current drugs are structurally related to either coumarin or indanedione. Representative drugs from each of these two groups have so far all been found to cause the accumulation of phylloquinone 2,3epoxide in the liver of rats by inhibiting reduction of the epoxide to the vitamin (Ren, Laliberte & Bell, 1974; Sadowski & Suttie, 1974) . In humans we have previously reported that phylloquinone 2,3-epoxide also accumulates in the plasma of warfarin-anticoagulated subjects (Shearer, McBurney & Barkhan, 1973) . These results suggest that all current clinical oral anticoagulants are inhibitors of the vitamin K1-epoxide cycle and that further insight into their mode of action in man might be gained from a study of their effect on the metabolism of phylloquinone.
Apart from measurements of the accumulation of phylloquinone 2,3-epoxide in the plasma, the isolation and characterization of the normal metabolites of phylloquinone from human urine Shearer, McBurney & Barkhan, 1974) provides a further technique to study the effect of warfarin on the metabolism of phylloquinone. We have shown that warfarin alters the pattern of conjugates in urine and blocks the excretion of the normal aglycones of phylloquinone in urine (Shearer et al., 1974) .
Whereas in our previous studies subjects were maintained on therapeutic doses of warfarin for several days before the vitamin study, we have now measured the effect of different single doses of warfarin on the metabolism of a tracer dose of [1',2'-3H2]-phylloquinone. It was thought that changes in the metabolite pattern of phylloquinone in the plasma and urine might mirror the effect of each dose of warfarin on the vitamin K,-epoxide cycle in the liver.
Materials and methods

Materials
[ 1 ',2'-3HH,]Phylloquinone, specific radioactivity 98 Ci/mol (217 pCi/mg) (a gift from Hoffmann-La Roche and Co., Basle, Switzerland), was received as a micellar solution in sealed sterile ampoules containing 10 pCi (45 pg) per 0.5 ml of solvent (polyethylene glycol ester). Phylloquinone 2,3epoxide was synthesized from phylloquinone by the method of Tishler, Fieser & Wendler (1940) .
Warfarin [ 3-( a-acetonylbenzyl)-4-hydroxycoumarin] was obtained from BDH Ltd (Poole, Dorset, U.K.) as tablets of Marevan containing 1 mg, 5 mg or 10 mg of racemic sodium warfarin. The R(+) and S(-) enantiomers of acidic warfarin were a gift from Ward Blenkinsop Pharmaceuticals (Wembley, Middlesex, U.K.) and had optical purities of 925 % and 97.3 % respectively.
Subjects
Fourteen studies were conducted in eight normal males aged 20-32 years and weighing 51-78 kg. Approval for the administration of radioactive phylloquinone was obtained from the Isotope Advisory Panel of the Medical Research Council. Permission for the study was obtained from the Committee on Ethical Practice of Guy's Hospital and Medical School, and all subjects gave their informed consent.
Plan of study
For each warfarin study, the subject fasted overnight and ingested the dose of warfarin at about 08.00 hours. Exactly 2 h later 45 pg (10 pCi) of [1',2'-3H2]phylloquinone was injected intravenously into a forearm vein.
The subjects were allowed liquids at any time and 2 h after the injection of phylloquinone they were allowed to continue their normal diet. The doses of warfarin administered in each study ranged from 1 to 70 mg. 
General procedures
Prothrombin times. These were determined as previously described . Plasma warfarin concentrations. These were determined by the method of Lewis, Ilnicki & Carlstrom (1970) , which measures the R and S enantiomers equally. Radioactivity measurements. Scintillation counting was performed as previously described .
Lipid extraction. Total lipid extracts of plasma samples (1-4 ml) were prepared as previously described (Shearer, Barkhan & Webster, 1970) , except that the step in which the aqueous methanol phases were washed with chloroform was omitted. Measurement of [31ilphylloquinone and ['HIphylloquinone 2,3-epoxide in plasma. Total lipid extracts of plasma were subjected to reversedphase thin-layer chromatography as described by Shearer et al. (1973) except that the support was Kieselgel GFZs4 and the developing solvent was acetonelwater (88 : 12, vlv).
Total radioactivity of urine. This was measured by direct radioactivity countingof0.3 ml aliquots as previously described (Shearer et al., 1970) .
Fractionation of 3H-labelled metabolites from
urine. The first 8 h urine collection from each subject was fractionated as follows.
(1) To obtain the acidic fraction, urine adjusted to pH 2 was continuously extracted with diethyl ether for 20 h .
(2) To obtain the aglycone fraction, ether extracts from (1) above were subjected to either (a) /?-glucuronidase hydrolysis as described by (3) The aglycones obtained from (2) above were either (a) distributed between chloroform and water or (b) methylated with diazomethane and subjected to adsorption thin-layer chromatography. Details of these procedures have been given previously . For thin-layer chromatography the solvent system was chloroform/diethyl ether (9:1, v/v). After development the distribution of radioactivity in 1 cm bands of adsorbant was determined as p r e viously described .
Results
Plasma measurements
Warfarin. Details of the plasma concentration Disappearance of [ 'H~hylloquinone. Over the period 0-8 h the form of the curve of the disappearance of unchanged phylloquinone from the plasma was similar for all subjects and as previously reported (Shearer et al., 1974) could be resolved graphically into two major exponential components.
The to.a values for these exponential components ranged from 23 to 36 min for the fast component and from 116 to 260 min for the slow component. There was no relationship, however, between these half-lives and the dose of warfarin administered.
[ 'H]Phylloquinone 2,3-epoxide. The plasma timecourse of [3H]phylloquinone 2,3-epoxide over 8 h for the control study and for five representative studies in subjects who were given 1, 3, 5 or 10 mg doses of racemic warfarin or 50 mg of S warfarin are shown in Fig. 1 .
After 1 mg (14 pg/kg body wt.) of racemic warfarin, the plasma concentrations of ["HIphylloquinone epoxide fell continuously after injection of [ 1',2'-3H,]phylloquinone and were similar to those found in the control study. In both these studies, the low but significant radioactivity associated with carrier phylloquinone epoxide probably represented trailing from more polar metabolites which travelled above phylloquinone epoxide in the reversedphase thin-layer-chromatography system.
After 3 mg (39 pg/kg body wt.) of racemjc warfarin, the plasma concentrations of ['HIphylloquinone epoxide were raised and from 1 to 8 h were two to three times greater than the corresponding values for the control study (Fig. 1) . Increasing the dose of warfarin caused increased amounts of phylloquinone epoxide to accumulate in the plasma (Fig. 1) . For higher doses of warfarin, the time-courses of phylloquinone epoxide in the plasma resembled those previously observed in subjects maintained on therapeutic doses of warfarin (Shearer et al., , 1974 . In all subjects peak concentrations of [3H]phylloquinone epoxide in the plasma occurred 2-4 h after the injection of phylloquinone; thereafter the plasma concentration fell exponentially with to., values ranging from 3 to 12 h.
If the accumulation of phylloquinone epoxide in the plasma is considered as a measure of the response to a given dose of warfarin, a doseresponse curve may be constructed in which the log of the warfarin dose is plotted against the peak plasma concentrations of phylloquinone epoxide. For various doses of racemic warfarin, a typical sigmoidal dose-response curve was obtained (Fig. 2) , which was essentially linear for doses between 50 and 300 pg/kg body wt. This dose range corresponds to single doses of warfarin of about 3-20 mg and approximates to the daily doses required for anticoagulant therapy.
Since for each study the plasma concentrations of warfarin did not vary greatly over the 8 h period during which estimations of ['HIphylloquinone epoxide were made, we also examined the relationship between the mean plasma warfarin concentrations over this period and the peak values of ["H]phylloquinone epoxide. There was a correlation (P<O.001) between the log of the plasma warfarin concentration and the peak plasma value of [ 3Hlphylloquinone epoxide, the regression line being given by the equation y = 306.9 log x + chloroform and water revealed that, after extraction with diethyl ether, about 80% of the radioactivity was still present as water-soluble metabolites, previously attributed to conjugated metabolites (Shearer et al., 1974) .
Distribution studies were also used to detect the possible hydrolysis of these conjugates to lipid-soluble aglycones, either enzymically by pglucuronidase or by the mild physical pro- 277.6 (r = 0.94, n = 9), where x represents the plasma warfarin concentration.
Urine measurements
Phylloquinone is normally excreted in human urine as two closely related compounds which have been identified as the glucuronide conjugates of 2-methyl-3-(5'-carboxy-3'-methyl-2'-pentenyl)-1,4naphthaquinone (metabolite I), and 2-methyl-3-(3'-carboxy-3'methylpropyl)-l, enaphthaquinone (metabolite 11) Shearer et al., 1974; McBurney, 1975) . The excretion of these compounds is greatly reduced in subjects maintained on therapeutic doses of warfarin. Instead abnormal metabolites are excreted which differ from metabolites I and I1 in the structures of both the conjugate and aglycone moieties (Shearer et al., 1974) . One of the objectives of this study was to relate these changes in metabolites in urine to the dose and/or plasma concentration of warfarin.
Nature of conjugates of phylloquinone in urine. The total excretion of radioactivity varied between subjects from 3 to 23% for the first 8 h, and from 14 to 36% for the 0-48 h period. The acidic nature of the major fraction of metabolites of phylloquinone in urine was shown by the finding that 6147% of the radioactivity in the 0-8 h urine collections could be recovered by continuous extraction with diethyl ether at pH 2. There was no relationship, however, between this acidic fraction and the dose of warfarin administered.
Measurements of the distribution of radioactive metabolites between equal volumes of reduction from 85 to 55% in the fraction of conjugates whichwas hydrolysed by /?-glucuronidase and an increase from 20 to 40% in a more labile conjugate fraction which was hydrolysed by solvolysis.
Nature of aglycones of phylloquinone in urine. Molecular differences in the structure of the aglycone moieties of metabolites of phylloquinone in urine were detected by comparing the distribution patterns of radioactivity on thin-layer chromatograms. Representative chromatograms of labelled aglycones obtained by pglucuronidase hydrolysis are shown in Fig. 3 . The chromatogram of the aglycone fraction from the control study (Fig. 3a) revealed only one radioactive peak (peak Ad, which has been previously shown to contain both the normal aglycones of phylloquinone in urine (metabolites I and 11) as their methyl esters (Shearer et al., 1974) . The effect of doses of 10 mg (197 ,ug/kg body wt.) and 50 mg (668 pg/kg body wt.) of racemic warfarin on the distribution pattern of radioactivity is shown in Fig. 3(b) and Fig. 3(c) . As the dose of warfarin was increased, peak At progressively declined and there was a concomitant increase in the excretion of more polar aglycones, which chromatographed as three distinct peaks (peaks W1, W2 and Ws: Fig. 3b and Fig. 3c ).
Similar distribution patterns of radioactivity were also obtained for aglycone 'fractions obtained by solvolysis.
For each study, the value for peak A1, and hence for the normal metabolites I and 11, was expressed as a percentage of the value determined for the control study. From duplicate chromatograms in the control study, peak At accounted for 61.6% (range 60542.6%) of the total radioactivity recovered from the thin layers.
The fraction of radioactive aglycones which chromatographed as metabolites I and I1 was inversely proportional to the log of the dose of warfarin (Fig. 4) , and a similarly significant relationship was found when metabolites I and I1 were plotted against the log of the plasma concentration of warfarin (linear regression equation; y = 57.7-39.4 log x ; n = 9, r = -0.96, P <OXXIl).
Effect of warfarin on the metabolism of different doses of phylloquinone
The effect of a 50 mg loading dose of racemic warfarin on the metabolic fate of different doses of phylloquinone was investigated in a subject who in two separate studies was given 45 pg and 1045 pg of phylloquinone respectively. Despite the 20-fold difference in the dose of phylloquinone, the prothrombin times after 24 and 48 h were identical, suggesting that the synthesis of the vitamin K-dependent clotting factors was inhibited to the same extent in each study. Although each dose of phylloquinone was cleared from the plasma at the same rate, the concentrations of phylloquinone epoxide in the plasma were at all times lower for the 1045 pg dose and the peak concentration 22% less than for the 45 pg dose of phylloquinone.
For the metabolites in urine it was found that both the rate and total excretion of radioactive metabolites over the first 72 h was the same for each dose of phylloquinone. The fraction of water-soluble metabolites in the 0-8 h urine collection which was rendered lipid-soluble by p-glucuronidase was also similar. Thin-layer chromatography of the aglycones liberated by 8-glucuronidase revealed, however, that the proportion as the normal metabolites I and I1 was greater for the 1045 pg dose of phylloquinone, when they represented 32.3 % of the control value (23.9% for the 45 pg dose).
Effect oJ' R and S eriantiomers of warfarin on phylloquinone metabolism
In one subject two studies compared the effect of 50 mg doses of the separate R and S 0 0 I00 lo00 10 Dose of warfarin ( p g l k g body wl.) FIG. 4 . Relationship between the proportion of aglycones of phylloquinone in urine as metabolites I and I1 and the log of the warfarin dose. The proportion of radioactive aglycones which chromatographed as peak Al was determined for the first 8 h urine collection from each study (see Fig. 3 ) and the results are expressed as a percentage of the value obtained in the control study. 0, Subjects given various doses of racemic warfarin; 0 and A, subject given 764 pg/kg of S ( 0 ) or R (A) warfarin.
For racemic warfarin, the linear regression equation was y = 154~147~41ogx (r = -0.97, n = 10, P <
0.001).
enantiomers of warfarin on the metabolism of a 45 pg dose of phylloquinone. Although the timecourses and peak concentrations of [3H]-phylloquinone epoxide over 8 h were very similar for each enantiomer, the accumulation of the epoxide metabolite in the plasma was greater than that for equivalent doses of racemic warfarin (Fig. 2) . Measuremedts of the urinary excretion of phylloquinone showed that there were no differences between the effect of each enantiomer on either the total urinary excretion of radioactivity or on the fraction of labelled conjugates which were hydrolysed by 8-glucuronidase. Thin-layer chromatography of the aglycones revealed, however, that S warfarin was more effective in blocking the urinary excretion of metabolites I and 11, the proportion of aglycones as metabolites I and I1 being reduced to 14.6% of the control value by S warfarin, compared with 26% by R warfarin (Fig. 4) .
Relationship between plasma [3HLphylloquinone epoxide and =H-labelled metabolites I and II in urine
There was an inverse relationship between the peak concentration of phylloquinone epoxide in the plasma and the proportion of 3H-labelled aglycones in urine as metabolites I and 11, the correlation coefficient being highly significant (P <0.001). The regression line was given by the equationy = 763*4-7.8x(r = -0.93,n = 12), where x represents metabolites 1 and 11.
Discussion
Absorption of warfarin
It was assumed in the experimental design of these studies that each dose of warfarin would be rapidly absorbed, as shown by Breckenridge & Orme (1973) , and completely absorbed, as shown by O'Reilly, Aggeler & Leong (1963). In our studies the plasma concentrations after each dose of warfarin (ranging from 14 to loo0 pg/kg) did not vary significantly over the 8 h period of study. This suggests that the 2 h period between the ingestion of warfarin and the injection of phylloquinone was sufficient to allow for complete absorption of each dose of warfarin.
log Dose-response relationships and nature of warfarin receptor
The log dose-response relationships between the dose or plasma concentrationof warfarinand the changes in the metabolites of phylloquinone in plasma and urine are typical of those to be expected for a drug-receptor interaction, and suggest that warfarin interferes with a receptor involved in the normal metabolism of phylloquinone. The identification of phylloquinone epoxide as a major metabolite which accumullates in the plasma of warfarin-treated subjects suggests that this receptor is phylloquinone epoxide reductase, an enzyme that normally converts phylloquinone epoxide into phylloquinone.
A metabolic scheme which shows how the inhibition of phylloquinone epoxide reductase might account for our findings is shown in Fig. 5 . This scheme is based on the vitamin K I-epoxide cycle proposed by Matschiner and co-workers (Bell & Matschiner, 1972; Matschiner et al., 1974; Willingham & Matschiner, 1974) , but also incorporates data of the normal metabolism of phylloquinone in our previous studies (Shearer et al., 1974) . In the rat the inhibition of phylloquinone epoxide reductase by warfarin prevents the normal regeneration of phylloquinone via the vitamin Kl-epoxide cycle and causes phylloquinone epoxide to accumulate in the liver (Matschiner  et al., 1974) . In man the progressive inhibition of this enzyme by increasing doses of warfarin would account for both the increasing concentrations of phylloquinone epoxide in the plasma and, as more of the vitamin was trapped as the epoxide, for the decreased excretion of the normal aglycones of phylloquinone in urine, metabolites I and 11. The inverse relationship between the accumulation of phylloquinone epoxide in the plasma and the urinary excretion of metabolites I and I1 also suggests that these metabolites in plasma and urine were derived from the same metabolic pool of phylloquinone.
The effect of warfarin in blocking the urinary excretion of the normal metabolites I and I1 was accompanied in our studies by a corresponding increase in the excretion of at least three abnormal metabolites (denoted by radioactive peaks W1, Wz and W3 in Fig. 3 ). In Fig. 5 twofold. First, the increase in the excretion of the abnormal metabolites W,, Wz and W3 was paralleled by a corresponding reduction of the normal metabolites I and I1 (Fig. 3) , and this change in the excretion pattern was correlated with the concentration of phylloquinone epoxide in the plasma. Secondly, several abnormal metabolites of phylloquinone with ultraviolet-absorption spectra very similar to authentic phylloquinone epoxide have been isolated from the urine of warfarin-treated subjects (McBurney, 1975) . The effect of warfarin in reducing the proportion of labelled conjugates that could be hydrolysed by B-glucuronidase has been previously observed in subjects who had been maintained for several days on therapeutic doses of warfarin (Shearer et al., 1974; McBurney, 1975) . Evidence has been obtained that this decreased hydrolysis by 8-glucuronidase represents a real reduction in the excretion of metabolites of phylloquinone as glucuronides rather than to the presence of an inhibitor of 8-glucuronidase in the urine of warfarintreated subjects (McBurney, 1975) . Although no explanation can be offered for this effect, a similar decrease in the glucuronide fraction has been found for the urinary excretion of several steroid hormones after the administration of certain drugs (Bradlow, Zumoff, Fukushima, Hellman, Bickers, Alvares & Kappas, 1973) .
Relationship between inhibition of phylloquinone epoxide reductase and inhibition of prothrombin synthesis
Although warfarin has been shown to inhibit phylloquinone epoxide reductase in rats both in uivo (Matschiner et al., 1970) and in vitro , a direct and unequivocal correlation between the degree of this inhibition and the inhibition of prothrombin synthesis has not yet been established. When different coumarin anticoagulants were administered to rats, Sadowski & Suttie (1974) concluded that the hepatic accumulation of phylloquinone epoxide found for each drug did not correlate with their relative effectiveness as anticoagulants. On the other hand, Bell, Caldwell & Holm (1976) did find that the degree of inhibition of prothrombin synthesis by two different coumarin anticoagulants (warfarin and coumatetralyl) was correlated with their inhibition of phylloquinone epoxide reductase, as measured by the ability of rats treated with various doses of these drugs to convert an injected tracer dose of [3Hlphyllo-quinone epoxide into phylloquinone.
The establishment of a correlation is rendered difficult in man by the fact that the degree of inhibition of prothrombin synthesis can only be estimated indirectly from measurements of the plasma levels of factors 11, VII, IX and X ('prothrombin complex' activity) . Since the plasma activity of 'prothrombin complex' reflects the net effect of both the rate of synthesis and degradation of the vitamin K-dependent clotting factors, the time of the maximum hypoprothrombinaemic response to oral anticoagulants is delayed when compared with the time of the peak concentrations of these drugs in the blood.
In an attempt to relate the anticoagulant effect of warfarin to its concentration in the plasma, Nagashima, O'Reilly & Levy (1969) derived a mathematical expression which defined the pharmacological effect of oral anticoagulants in terms of their effect on the rate of synthesis of 'prothrombin complex' activity. They further showed experimentally that when expressed in terms of the rate of synthesis of 'prothrombin complex' activity the pharmacological effect of warfarin followed the kinetics expected for a drug-receptor interaction, in which the response is linearly related to the log of the plasma concentration of warfarin.
In our study similar linear relationships were obtained between the log of the dose or plasma concentration of warfarin and specific changes in the metabolism of phylloquinone, as judged by both the accumulation of phylloquinone epoxide in the plasma, and also differences in the molecular nature of the aglycones of phylloquinone excreted in the urine. Our data therefore support the view that there is a close link between the pharmacological action of warfarin and the inhibition of vitamin K metabolism, and that the site of this inhibition is the enzyme phylloquinone epoxide reductase.
Metabolism of different doses of phylloquinone
Owing to the lack of quantitative data about vitamin K in the nutrition of man, it is not known how the 45 pg dose of phylloquinone used in our studies compares with the daily intake or body stores of vitamin K. Although Duello & Matschiner (1972) estimated that the concentration of vitamin K was equivalent to only 0.06 pg of phylloquinonelg (wet weight) of liver (suggesting that total human liver reserves of vitamin K are equivalent to about 50-100 pg of phylloquinone), further studies are necessary to establish the variation of vitamin K reserves between individuals.
In subjects maintained on therapeutic doses of warfarin, the timecourses for the accumulation of phylloquinone epoxide in the plasma were similar for both 1 mg and 45 pg doses of phylloquinone (Shearer et al., 1974) . In the two studies reported here, the anticoagulant response to 50 mg of warfarin was the same for 45 and 1045 p u g doses of phylloquinone. However, the decreased concentrations of phylloquinone epoxide in the plasma after the 1045 pg dose, together with the increased excretion of metabolites I and 11 in the urine, suggest that the proportion of this dose which was converted into and trapped as the epoxide was slightly less than for the 45 pg dose of phylloquinone. Since these differences in metabolism were small compared with the difference in dose, it is concluded that even quite large variations in the liver reserves of vitamin K would not greatly influence the metabolism of our 45 pg test dose of phylloquinone.
Effect of R and S enantiomers of warfarin on phylloquinone metabolism
The R(+) and S(-) enantiomers of which commercial warfarin is an equal mixture have been found to differ both in their rate and pathway of metabolism, and also in their intrinsic potency as anticoagulants. In man S warfarin is three to four times more effective as an inhibitor of prothrombin synthesis than the R enantiomer (Breckenridge, Orme, Wesseling, Lewis & Gibbons, 1974; OReilly, 1974) .
In a preliminary experiment we found that S warfarin was about twice as effective as R warfarin in blocking the urinary excretion of metabolites I and 11. On the other hand, the almost identical plasma concentrations and time-courses of phylloquinone epoxide suggested an apparent equal effectiveness for the enantiomers. It is probable, however, that the similar plasma concentrations of phylloquinone epoxide reflected the saturation kinetics found for racemic warfarin (Fig. 2) and that the dose of each enantiomer exceeded that required for the maximal accumulation of phylloquinone epoxide.
Products Ltd, Welwyn Garden City, Hertfordshire, U.K., and F. Hoffmann-La Roche and Co., Basle, Switzerland, for the supply of tritium-labelled phylloquinone used in these studies, and to Ward Blenkinsop Pharmaceuticals, Wembley, Middlesex, U.K., for the gifts of the enantiomers of warfarin. The work was supported by a grant from the Medical Research
Council.
